Lista de obras -

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

artículo científico publicado en 2002

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

scientific article published on 08 May 2018

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

artículo científico publicado en 2014

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

artículo científico publicado en 2011

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

artículo científico publicado en 2002

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

artículo científico publicado en 2009

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy

artículo científico publicado en 2014

Bortezomib in the front-line treatment of multiple myeloma

artículo científico publicado en 2008

Bortezomib in the management of multiple myeloma ⬇️

artículo científico publicado el 8 de septiembre de 2009

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

artículo científico publicado en 2008

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

artículo científico publicado en 2012

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

artículo científico publicado en 2010

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

artículo científico publicado en 2010

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

artículo científico publicado en 2015

Emerging drugs in multiple myeloma

artículo científico publicado en 2007

Emerging trends in the clinical use of bortezomib in multiple myeloma

artículo científico publicado en 2005

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

artículo científico publicado el 13 de diciembre de 2012

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function

artículo científico publicado en 2004

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2003

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

artículo científico publicado en 2005

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

artículo científico publicado en 2002

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

artículo científico publicado en 2002

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

artículo científico publicado en 2005

Lenalidomide after stem-cell transplantation for multiple myeloma

artículo científico publicado en 2012

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

artículo científico publicado en 2017

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

artículo científico publicado el 15 de junio de 2010

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

artículo científico publicado en 2010

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

artículo científico publicado en 2011

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

artículo científico publicado el 1 de junio de 2011

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

artículo científico publicado el 1 de octubre de 2011

Management of myeloma-associated renal dysfunction in the era of novel therapies

artículo científico publicado en 2012

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

artículo científico publicado el 7 de julio de 2011

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

artículo científico publicado en 2011

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

artículo científico publicado en 2002

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

artículo científico publicado en 2003

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

artículo científico publicado en 2009

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

artículo científico publicado en 2003

New drugs for myeloma

artículo científico publicado en 2007

New treatments for multiple myeloma.

artículo científico publicado en 2005

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

artículo científico publicado en 2007

Novel therapies in the treatment of multiple myeloma

artículo científico publicado en 2009

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

artículo científico publicado en 2007

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

artículo científico publicado en 2014

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

artículo científico publicado en 2016

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

artículo científico publicado en 2015

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

artículo científico publicado en 2014

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

artículo científico publicado en 2017

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial ⬇️

artículo científico publicado el 11 de octubre de 2011

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib ⬇️

artículo científico publicado el 14 de diciembre de 2012

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2006

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

artículo científico publicado en 2009

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

artículo científico publicado en 2010

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

artículo científico publicado en 2004

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

artículo científico publicado en 2002

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

artículo científico publicado en 2004

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma ⬇️

artículo científico publicado el 1 de febrero de 2011

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* ⬇️

artículo científico publicado el 22 de noviembre de 2011

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

artículo científico publicado en 2003

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib ⬇️

artículo científico publicado el 7 de marzo de 2012

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

artículo científico publicado en 2002

The treatment of multiple myeloma patients not eligible for asct ⬇️

artículo científico publicado el 3 de mayo de 2010

The treatment of relapsed and refractory multiple myeloma

artículo científico publicado en 2007

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

artículo científico publicado en 2002

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

artículo científico publicado en 2010

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

artículo científico publicado en 2017

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma

artículo científico publicado en 2003

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study

artículo científico publicado en 2011

Lista de obras de

2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells

A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma

A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma

A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma

Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications

Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.

Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy

Bortezomib in the front-line treatment of multiple myeloma

Bortezomib in the management of multiple myeloma ⬇️

Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw.

Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function

Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia

Conflicts of interest, authorship, and disclosures in industry-related scientific publications

Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations

Emerging drugs in multiple myeloma

Emerging trends in the clinical use of bortezomib in multiple myeloma

Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study ⬇️

Flowing cells through pulsed electric fields efficiently purges stem cell preparations of contaminating myeloma cells while preserving stem cell function

GW654652, the pan-inhibitor of VEGF receptors, blocks the growth and migration of multiple myeloma cells in the bone marrow microenvironment

Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma

Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications

Lenalidomide after stem-cell transplantation for multiple myeloma

Lenalidomide in combination or alone as maintenance therapy following autologous stem cell transplant in patients with multiple myeloma: a review of options for and against

Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy ⬇️

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Lenalidomide, bortezomib, pegylated liposomal doxorubicin, and dexamethasone in newly diagnosed multiple myeloma: a phase 1/2 Multiple Myeloma Research Consortium trial

MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias

Management of Relapsed and Relapsed/Refractory Multiple Myeloma ⬇️

Management of myeloma-associated renal dysfunction in the era of novel therapies

Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings ⬇️

Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341.

Molecular sequelae of histone deacetylase inhibition in human malignant B cells

Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma

NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma

New drugs for myeloma

New treatments for multiple myeloma.

Novel therapeutic avenues in myeloma: changing the treatment paradigm.

Novel therapies in the treatment of multiple myeloma

Novel therapy with 2-methoxyestradiol for the treatment of relapsed and plateau phase multiple myeloma

Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide

Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: outcomes by prior treatment

Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

Panobinostat plus bortezomib and dexamethasone: impact of dose intensity and administration frequency on safety in the PANORAMA 1 trial.

Perifosine Plus Bortezomib and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With Bortezomib: Results of a Multicenter Phase I/II Trial ⬇️

Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib ⬇️

Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

Tailoring treatment for multiple myeloma patients with relapsed and refractory disease

Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells

Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu

Thalidomide for patients with relapsed multiple myeloma after high-dose chemotherapy and stem cell transplantation: results of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity

Thalidomide, lenalidomide and bortezomib in the management of newly diagnosed multiple myeloma ⬇️

The Medical Research Council Myeloma IX trial: the impact on treatment paradigms* ⬇️

The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance

The potential benefits of participating in early‐phase clinical trials in multiple myeloma: long‐term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib ⬇️

The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications

The treatment of multiple myeloma patients not eligible for asct ⬇️

The treatment of relapsed and refractory multiple myeloma

The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment

Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity.

Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial

Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma

Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study